Company Name

Melys Diagnostics Ltd

Description of company/ product

Chronic Atrial Fibrillation (AF) is the commonest arrhythmia seen in medical practice.  It accounts for 33% of strokes in elderly people, and there is a six-fold increase in thromboembolic incidents.  Many patients with the condition are not identified.  Diagnosing the condition involves the patient taking an electrocardiogram (ECG).  ECGs are expensive and therefore not used for mass screening.  The Melys Diagnostics Atrial Fibrilation Screening Monitor provides a low-cost means of objectively detecting an irregular pulse, enabling a medical practitioner to identify previously unidentified potential sufferers, and to refer only those patients with arrhythmia for ECG examination. 

Key Selling points

1. Identifies potential Atrial Fibrilation sufferers.
2. Non-invasive, simple to use technique.
3. Inexpensive screening monitor.
4. Can be used in medical centres, pharmacies, and in the home.

Looking for:

We are looking for a joint venture with a company which can take the monitor to production, marketing and sales.

Patent Status:

New International Application PCT/GB2007/050280.  Filed May 2007.

Potential Markets/ outlets

GP surgeries, pharmacies and home healthcare.